186 related articles for article (PubMed ID: 25495953)
1. Digital plethysmography and arginine metabolism in prehypertension: effect of nebivolol therapy.
Kandavar R; Fernandez C; Sander GE; Kim C; Velaga S; Sukhanov S; Delafontaine P; Egan P; Roffidal LE; Giles TD
J Clin Hypertens (Greenwich); 2015 Jan; 17(1):14-9. PubMed ID: 25495953
[TBL] [Abstract][Full Text] [Related]
2. Are all β-blockers the same? Nebivolol vasodilator properties and evidence for relevance in treatment of hypertension.
Kanbay M; Afsar B
J Clin Hypertens (Greenwich); 2015 Jan; 17(1):20-1. PubMed ID: 25440024
[No Abstract] [Full Text] [Related]
3. Nebivolol treatment reduces serum levels of asymmetric dimethylarginine and improves endothelial dysfunction in essential hypertensive patients.
Pasini AF; Garbin U; Stranieri C; Boccioletti V; Mozzini C; Manfro S; Pasini A; Cominacini M; Cominacini L
Am J Hypertens; 2008 Nov; 21(11):1251-7. PubMed ID: 18772860
[TBL] [Abstract][Full Text] [Related]
4. The effect of nebivolol versus metoprolol succinate extended release on asymmetric dimethylarginine in hypertension.
Kandavar R; Higashi Y; Chen W; Blackstock C; Vaughn C; Sukhanov S; Sander GE; Roffidal LE; Delafontaine P; Giles TD
J Am Soc Hypertens; 2011; 5(3):161-5. PubMed ID: 21251896
[TBL] [Abstract][Full Text] [Related]
5. The effect of nebivolol on asymmetric dimethylarginine system in spontaneously hypertension rats.
Wang Y; Zhang M; Liu Y; Liu Y; Chen M
Vascul Pharmacol; 2011; 54(1-2):36-43. PubMed ID: 21167314
[TBL] [Abstract][Full Text] [Related]
6. Nebivolol reduces asymmetric dimethylarginine in endothelial cells by increasing dimethylarginine dimethylaminohydrolase 2 (DDAH2) expression and activity.
Garbin U; Pasini AF; Stranieri C; Manfro S; Boccioletti V; Cominacini L
Pharmacol Res; 2007 Dec; 56(6):515-21. PubMed ID: 17977009
[TBL] [Abstract][Full Text] [Related]
7. Nebivolol: endothelium-mediated vasodilating effect.
Ritter JM
J Cardiovasc Pharmacol; 2001 Dec; 38 Suppl 3():S13-6. PubMed ID: 11811387
[TBL] [Abstract][Full Text] [Related]
8. Nebivolol reverses endothelial dysfunction in essential hypertension: a randomized, double-blind, crossover study.
Tzemos N; Lim PO; MacDonald TM
Circulation; 2001 Jul; 104(5):511-4. PubMed ID: 11479245
[TBL] [Abstract][Full Text] [Related]
9. Nebivolol therapy improves endothelial function and increases exercise tolerance in patients with cardiac syndrome X.
Sen N; Tavil Y; Erdamar H; Yazici HU; Cakir E; Akgül EO; Bilgi C; Erbil MK; Poyraz F; Okyay K; Turfan M; Cemri M
Anadolu Kardiyol Derg; 2009 Oct; 9(5):371-9. PubMed ID: 19819787
[TBL] [Abstract][Full Text] [Related]
10. Nebivolol in high-risk, obese African Americans with stage 1 hypertension: effects on blood pressure, vascular compliance, and endothelial function.
Merchant N; Searles CD; Pandian A; Rahman ST; Ferdinand KC; Umpierrez GE; Khan BV
J Clin Hypertens (Greenwich); 2009 Dec; 11(12):720-5. PubMed ID: 20021529
[TBL] [Abstract][Full Text] [Related]
11. Nebivolol: impact on cardiac and endothelial function and clinical utility.
Toblli JE; DiGennaro F; Giani JF; Dominici FP
Vasc Health Risk Manag; 2012; 8():151-60. PubMed ID: 22454559
[TBL] [Abstract][Full Text] [Related]
12. Nitric-oxide-mediated relaxations in salt-induced hypertension: effect of chronic beta1 -selective receptor blockade.
Cosentino F; Bonetti S; Rehorik R; Eto M; Werner-Felmayer G; Volpe M; Lüscher TF
J Hypertens; 2002 Mar; 20(3):421-8. PubMed ID: 11875309
[TBL] [Abstract][Full Text] [Related]
13. Vascular effects of nebivolol added to hydrochlorothiazide in African Americans with hypertension and echocardiographic evidence of diastolic dysfunction: the NASAA study.
Khan BV; Rahman ST; Haque T; Merchant N; Bhaheetharan S; Harris J; Umar K; Wahi J; Ferdinand KC
J Cardiovasc Pharmacol Ther; 2012 Sep; 17(3):291-7. PubMed ID: 22388001
[TBL] [Abstract][Full Text] [Related]
14. Nebivolol vasodilates human forearm vasculature: evidence for an L-arginine/NO-dependent mechanism.
Cockcroft JR; Chowienczyk PJ; Brett SE; Chen CP; Dupont AG; Van Nueten L; Wooding SJ; Ritter JM
J Pharmacol Exp Ther; 1995 Sep; 274(3):1067-71. PubMed ID: 7562470
[TBL] [Abstract][Full Text] [Related]
15. Exploring vascular benefits of endothelium-derived nitric oxide.
Cockcroft JR
Am J Hypertens; 2005 Dec; 18(12 Pt 2):177S-183S. PubMed ID: 16373196
[TBL] [Abstract][Full Text] [Related]
16. Central hemodynamics in prehypertension: effect of the β-adrenergic antagonist nebivolol.
Davis JT; Pasha DN; Khandrika S; Fung MM; Milic M; O'Connor DT
J Clin Hypertens (Greenwich); 2013 Jan; 15(1):69-74. PubMed ID: 23282127
[TBL] [Abstract][Full Text] [Related]
17. Nebivolol: haemodynamic effects and clinical significance of combined beta-blockade and nitric oxide release.
Kamp O; Metra M; Bugatti S; Bettari L; Dei Cas A; Petrini N; Dei Cas L
Drugs; 2010; 70(1):41-56. PubMed ID: 20030424
[TBL] [Abstract][Full Text] [Related]
18. Nebivolol: a highly selective beta1-adrenergic receptor blocker that causes vasodilation by increasing nitric oxide.
Gupta S; Wright HM
Cardiovasc Ther; 2008; 26(3):189-202. PubMed ID: 18786089
[TBL] [Abstract][Full Text] [Related]
19. Effect of nebivolol on blood oxygen transport indices and endothelial dysfunction in patients with arterial hypertension.
Pronko TP; Zinchuk VV
Clin Physiol Funct Imaging; 2009 May; 29(3):170-6. PubMed ID: 19170724
[TBL] [Abstract][Full Text] [Related]
20. Effects of the vasodilating beta-blocker nebivolol on smoking-induced endothelial dysfunction in young healthy volunteers.
Schmidt AC; Flick B; Jahn E; Bramlage P
Vasc Health Risk Manag; 2008; 4(4):909-15. PubMed ID: 19066009
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
